Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(...
And, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 700,000 shares of its common stock at ...
X4 Pharmaceuticals (NASDAQ:XFOR) ("X4" or the "Company"), a company driven to improve the lives of people with ...
Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of...
Stifel analyst Stephen Willey maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers the price target from $30 to $9.
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers the ...
